TriSalus Life Sciences offers Pressure-Enabled Drug Delivery technology through devices such as the TriNav infusion system for liver tumors and a retrograde venous system for pancreatic tumors. These systems improve the delivery of therapeutics past vascular barriers in solid tumors. The company is also developing nelitolimod, an investigational immunotherapy, for combination use in liver and pancreatic cancer treatment.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 11.2 | — | -9 | — |
| Q3 2025 | 11.6 | — | -41.3 | — |
| Q4 2025 | 13.2 | — | -9.8 | — |
| Q1 2026 | 8.9 | — | 1.5 | — |
| Q2 2026 | 11.4 | 1.7% | -9.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: 1RT Acquisition Corp. (ONCH), Microvast Holdings, Inc. (MVST), Bitzero Holdings Inc. (AIBZ), Nature's Sunshine Products, Inc. (NATR), Uxin Limited (UXIN), BioAge Labs, Inc. (BIOA)